Premium
Intermittent guanazole therapy in adult acute leukemia
Author(s) -
Hewlett James S.,
Bodey Gerald P.,
Coltman Charles A.,
Freireich Emil J.,
Haut Arthur B.,
McCredie Kenneth B.
Publication year - 1973
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt1973142271
Subject(s) - medicine , complete remission , leukemia , chronic myelogenous leukemia , acute leukemia , gastroenterology , chemotherapy , surgery
Guanazole is a specific inhibitor of DNA synthesis. It has shown marked schedule dependency in the treatment of L1210 leukemia. In a Phase II study guanazole was giveTi in an induction dose of 7.5 gm per square meter per day for 5 days by continuous intravenous infusion and repeated every 14 days. Twenty‐four leukemic patients received an adequate trial (3 or more courses). There were 4 complete remissions, 2 partial remissions, 4 hematologic responses, and 34 failures. Complete remissions occurred in 3 patients with acute myelogenous leukemia lasting 49 days in 1, and 2 patients were still in complete remission 451 and 230 days after treatment. One patient with chronic myelogenous leukemic blast transformation achieved a complete remission lasting 99 days. Myelosuppression was the maior toxic effect.